Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 6, 2026 | −$8.45 | −641.7% | $7.80B | +10.2% | −$7.24 |
| Q1 FY26ended Mar 31, 2026 | May 7, 2026 | $1.61 | +54.8% | $6.96B | +4.4% | $1.89 |
| Q4 FY25ended Dec 31, 2025 | — | $1.74 | +23.4% | $7.93B | +4.7% | — |
| Q3 FY25ended Sep 30, 2025 | — | $2.43 | +143.0% | $7.77B | +3.0% | — |
| Q2 FY25ended Jun 30, 2025 | — | $1.56 | +20.9% | $7.08B | +1.8% | — |
| Q1 FY25ended Mar 31, 2025 | — | $1.04 | — | $6.67B | −0.3% | — |
| Q4 FY24ended Dec 31, 2024 | — | $1.41 | +23.7% | $7.57B | +6.4% | — |
| Q3 FY24ended Sep 30, 2024 | — | $1.00 | −42.2% | $7.55B | +7.0% |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Gilead Sciences shares, not any token. As of Aug 6, 2026, from Massive's standardised financials and the earnings calendar.
| — |
| Q2 FY24ended Jun 30, 2024 | — | $1.29 | — | $6.95B | — | — |
| Q1 FY24ended Mar 31, 2024 | — | −$3.34 | — | $6.69B | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $1.14 | — | $7.11B | — | — |
| Q3 FY23ended Sep 30, 2023 | — | $1.73 | — | $7.05B | — | — |